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Summary
X-linked liver glycogenosis (XLG) is probably the most
frequent glycogen-storage disease. XLG can be divided
into two subtypes: XLG I, with a deficiency in phos-
phorylase kinase (PHK) activity in peripheral blood cells
and liver; and XLG II, with normal in vitro PHK activity
in peripheral blood cells and with variable activity in
liver. Both types of XLG are caused by mutations in the
same gene, PHKA2, that encodes the regulatory a sub-
unit of PHK. To facilitate mutation analysis in PHKA2,
we determined its genomic structure. The gene consists
of 33 exons, spanning 65 kb. By SSCP analysis of the
different PHKA2 exons, we identified five new XLG I
mutations, one new XLG II mutation, and one mutation
present in both a patient with XLG I and a patient with
XLG II, bringing the total to 19 XLG I and 12 XLG II
mutations.Most XLG Imutations probably lead to trun-
cation or disruption of the PHKA2 protein. In contrast,
all XLG II mutations are missense mutations or small
in-frame deletions and insertions. These results suggest
that the biochemical differences between XLG I and
XLG II might be due to the different nature of the dis-
ease-causing mutations in PHKA2. XLG I mutations
may lead to absence of the a subunit, which causes an
unstable PHK holoenzyme and deficient enzyme activity,
whereas XLG II mutations may lead to in vivo dereg-
ulation of PHK, which might be difficult to demonstrate
in vitro.
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Introduction
Protein kinases are very important enzymes controlling
numerous physiological processes by transferring phos-
phate from ATP to different protein substrates. Phos-
phorylase kinase (PHK), the prototype of protein ki-
nases, plays a regulatory role in a cascade of enzymatic
reactions controlling glycogen breakdown. PHK consists
of four different subunits: a, b, g, and d. The g subunit
harbors the catalytic activity and is regulated by phos-
phorylation of the a and b subunits and by interaction
of Ca2 with the d subunit, which is calmodulin (see
Hendrickx and Willems 1996). Several isoforms exist
for all of these different subunits. Some of these isoforms
are encoded by different genes, whereas others result
from differential splicing of the same gene (Hendrickx
and Willems 1996). Two genes encoding the a subunit
(Wu¨llrich et al. 1993; Hirono et al. 1995), one gene
encoding the b subunit (Wu¨llrich-Schmoll and Kilimann
1996), two genes encoding the g subunit (Hanks 1989;
Wehner and Kilimann 1995), and three calmodulin
genes (Wawrzynczak and Perham 1984; Sen Gupta et
al. 1987; Fischer et al. 1988) have been isolated. Most
of these genes have already been implicated in different
glycogen-storage disorders.
X-linked liver glycogenosis (XLG [MIM 306000]) is
probably the most common inherited disorder of gly-
cogen metabolism (Huijing and Fernandes 1969). XLG
is caused by a genetic deficiency of PHK. It is a relatively
mild disease, which is mainly characterized by hepato-
megaly and growth retardation during childhood (Huij-
ing and Fernandes 1969; Schimke et al. 1973; Lederer
et al. 1975; Willems et al. 1990). Two types, XLG I and
XLG II, have been described. Both types of patients show
very similar clinical symptoms. However, patients with
XLG I show a clear in vitro enzyme deficiency of PHK
in erythrocytes, leukocytes, and liver (Huijing and Fer-
nandes 1969), whereas XLG II patients show normal or
even elevated in vitro PHK enzyme activity in erythro-
cytes and leukocytes and varying activity in liver (Hen-
drickx et al. 1994). Both types of XLG have been shown
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Table 1
Patients Included in Mutation Analysis
PATIENT TYPE OF XLG
PHK ACTIVITYa
(% OF THE CONTROL MEAN)
DESCENT MUTATIONErythrocytes Liver
1 I 5.6 ND United Kingdom Q1169X
2 I 8.7 ND United Kingdom fs100
3 I 6.9 ND Belgium fs1119
4 I 10.0 6.2 United Kingdom fs226
5 I 27.2 ND United Kingdom E1125K
6 II 177.0 ND United Kingdom DK189–T190
7 II 123.0 ND France R186H
8 II ND 80.0 United States R186C
9 I 10.0 10.0 United States R295H
10 II 83.0 ND United Kingdom R295H
a All enzyme assays have been performed with rabbit muscle phosphorylase as a substrate; ND 
not determined.
to be caused by mutations in the PHKA2 gene, which
encodes the liver a subunit of PHK (Hendrickx et al.
1995, 1996, 1998; Hirono et al. 1995; van den Bergh
et al. 1995; Burwinkel et al. 1996, 1998). The XLG I
mutations include four nonsense mutations (Hendrickx
et al. 1995; Burwinkel et al. 1998), two frameshift mu-
tations (Burwinkel et al. 1998), one splice-site mutation
(Hendrickx et al. 1995), three missense mutations (van
den Bergh et al. 1995; Burwinkel et al. 1998), and three
in-frame deletions (van den Bergh et al. 1995; Burwinkel
et al. 1998), whereas the XLG II mutations include eight
missense mutations (Hirono et al. 1995; Burwinkel et
al. 1996, 1998; Hendrickx et al. 1996, 1998), a deletion
of one amino acid, and an insertion of two amino acids
(Hendrickx et al. 1996). The different nature of XLG I
and XLG II mutations has previously led to the hy-
pothesis that XLG I mutations disrupt the PHKA2 pro-
tein, whereas XLG II mutations might affect the regu-
lation of the PHK enzyme (Hendrickx et al. 1996).
We have previously determined the partial genomic
structure and the intron-exon boundaries of the PHKA2
gene (Hendrickx et al. 1995). In the present study, the
complete genomic structure was determined, providing
primer sequences to perform mutation analysis using
exon-by-exon scanning, and a series of XLG I and XLG
II mutations was identified.
Patients and Methods
Patients
Mutation analysis was performed in 10 unrelated pa-
tients (table 1). All patients are male and show hepa-
tomegaly, delayed growth in childhood, and elevation
of serum transaminases. The PHK activity in liver and
erythrocytes is shown in table 1. Patient 5 belongs to
one of the families involved in the genetic localization
of the XLG I gene (Hendrickx et al. 1993). Clinical and
biochemical data on patient 8 (Keating et al. 1985) and
patient 9 (Tuchman et al. 1986) have been published
previously. Patient 7 belongs to the group 2 (i.e., XLG
II) patients, described by Maire et al. (1991), who have
a normal erythrocyte PHK activity when the latter is
measured with exogenous phosphorylase as a substrate
but who have a deficient activity when it is measured
with endogenous phosphorylase.
PCR
PCR was performed in a 25-ml reaction volume con-
taining 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.01%
(w/v) gelatin, 1.5 mM MgCl2, 0.1% (v/v) Triton X100,
1 mM of each primer (table 2), and 0.4 mM of each
dNTP, by use of 0.2 U Taq DNA polymerase (Eurogen-
tec). Detailed PCR conditions are available.
Subcloning of Genomic Clones
Approximately 1 mg cosmid or P1 clone was diluted
to 250 ml in 10 mM Tris-HCl pH 7.4, 0.1 mM EDTA
and was sonicated to obtain fragments of an average
length of 500 bp. To generate blunt-ended fragments,
T4 DNA polymerase was used. The fragments were pre-
cipitated with ethanol and were treated with 30 U T4
DNA polymerase for 20 min at room temperature in a
50-ml reaction volume containing 50 mM Tris-HCl (pH
8.0), 5mM MgCl2, 50 mM DTT, 5 mg BSA/ml, and 0.1
mM of each dNTP. Subsequently, the fragments were
ligated into the SmaI restriction site of pUC18 by use
of the SureClone ligation kit (Pharmacia). Alternatively,
genomic clones were digested with Sau3A and were li-
gated into the BamHI site of pUC18 by use of the Ready
To Go ligation kit (Pharmacia).
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Table 2
PHKA2 Exons and Primers Used for SSCP Analysis
NUMBER
EXON SIZE
(bp)a POSITION
INTRON SIZE
(kb)
PRIMERb
FRAGMENT SIZE
(bp)
ANNEALING
TEMPERATURE
(˚C)Forward Reverse
1 204 171–78 5.0 cggcctgggagcctcggggag gagaatgagttacatgagaag 159 48
2 159 79–237 1.5 cagccgagatacagctgtcag cagcggagatacgctgtcag 234 55
3 48 238–285 1.1 gggccgtgttgctgattctgc tttatcctctgactttctgac 121 50
4 169 286–454 2.5 cccccataactatgcagagcg actccttatacaatgggctcc 246 55
5 82 455–537 3.6 gcaacatggcttcataagctc ggaacatctgaaaagactacc 156 55
6 80 538–618 1.4 ctctttctcccctctgattcc gcagaaggaagaacaaacagg 151 55
7 99 619–717 2.3 aaaaggaacaccagatattgg cttccctgctctctgaaatgc 238 55
8 147 718–864 1.3 gcctattacgcatctccagg catcgacacaggacagaagg 238 55
9 54 865–918 1.6 ctctgagctcatcgaatgtac ttagagatgaaacagttgagg 138 50
10 123 919–1041 2.5 tgtatgtattctgacatcacc attatcaacgtaacacccagc 204 55
11 96 1042–1137 4.2 ccttcctgccatggatgatgg tagataagcggtgcaaagggc 169 55
12 108 1138–1245 2.8 tttatcctctgactttctgac cctgaacctccaattacatgg 203 55
13 79 1246–1324 .6 atgkgcagtagacacgctcac ttcatagtgataatgctcctc 134 55
14 135 1325–1459 .8 gacaagagtcatgagctaacg caaatctagaaccgagatgcc 240 48
15 110 1460–1569 .7 aaccgtatttcctctaactcc aaaagatgctcgttggcctgc 186 55
16 145 1570–1714 .2 tccaggtaaagaaagggtggc tttgtaagagcccaaccaccc 253 55
17 79 1715–1793 2.7 ctgcccagactaaactaattc taagaaaggtcagtgctactc 168 55
18 170 1794–1963 1.5 tccacacactacctgtttccc cagcgaactacccanaaaagc 234 55
19 174 1964–2137 12.0 ctacagcttggtttcattggc agaaggtattttaacaggcag 260 55
20 89 2138–2226 1.8 gtgttgttcttcctcctc gccattgtagaaacaccatac 195 48
21 134 2227–2360 .7 atgcctagccgatctccctgc cctaagccattctgttcatgg 237 52
22 157 2361–2517 .9 tttctgggtttttctacctc gagattggaagtggaagagg 252 55
23 80 2518–2597 .2 gttgtctgcctctcacccttc gcaaacctgaggtccccaagg 149 55
24 79 2598–2676 .1 tgttccatggagggcgaggag tccactctgaggaaggctgtg 200 55
25 130 2677–2806 .6 ccctgtctctgaaaccctatc tgcgcggagctgcaggagctg 204 55
26 102 2807–2908 .7 gatttaaacggcagcatttag agtgctggttctaatgtctgc 369 52
27 119 2909–3027 .9 gctgtagagttcctgagaacc ctgtcgctttctggggtaagc 233 50
28 30 3028–3057 1.5 gcgtctgctcaaagctgg actttccacattcaagcc 141 48
29 54 3058–3111 1.7 ttggtgtcattgctgtca gggacggacacaataatc 140 52
30 171 3112–3282 2.0 ggctgcgtggcttctgaggcc gctgtgtgtttgcttgcctg 304 62
31 54 3283–3336 .8 gaatctgactgaaatgcgctc cttattgtgaacccacagagg 139 55
32 201 3337–3537 .6 tggtggttgtctgcctgtccc ccagcmaacccagctccctgg 261 55
33 896 3538–4433 ) gtggggctccgcttattgtcc tcatgtttccaggtgagaccc 234 57
a The discrepancy between the length of exons 20 and 21 in this report and that in the study by Hendrickx et al. (1995) is due to errors in
the 1995 study.
b Except for the forward primer of exon 1, which is located in the 5′ UTR, and the reverse primer of exon 33, which is located in the 3′
UTR, all primers are located in PHKA2 introns.
Hybridizations
Probes were radioactively labeled with a-[32P]dCTP
by use of the T7 QuickPrime kit (Pharmacia). Hybrid-
izations were performed overnight in 10# Denhardt’s,
10% (w/v) dextran sulfate, 0.1% (w/v) SDS, and 3 #
SSC at 65˚C. Washing was performed in 1# SSC, 0.1%
(w/v) SDS for 30–45 min at 65˚C.
SSCP Analysis
Radioactive PCR was performed, as described above,
in the presence of 1 mCi a-[32P]dCTP. Annealing tem-
peratures were optimized for the different primer sets
(table 2). SSCP analysis was performed on a 0.5#Mu-
tation Detection Enhancement (MDE) gel (Baker) in 0.6
# Tris-borate EDTA (TBE) containing 10% (v/v) glyc-
erol at room temperature and on a 0.5 # MDE gel in
0.6# TBE without glycerol at 4˚C. Electrophoresis was
performed overnight at 400 V.
Sequence Analysis
PCR products were ligated into either pUC18, by use
of the SureClone ligation kit (Pharmacia), or pT-Adv, by
use of the AdvanTage PCR cloning kit (Clontech), prior
to being sequenced. Alternatively, PCR products were
purified from agarose gels by use of the Sephaglas
BandPrep kit (Pharmacia) and were sequenced directly.
Sequence reactions were performed with the PRISM
ready-reaction dye-terminator kit (Perkin-Elmer) and
were analyzed on an ABI 373 automated sequencer.
To exclude the possibility of PCR artifacts, all mu-
tations have been confirmed by either PCR or modified
PCR on genomic DNA from the patient, followed by
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Figure 1 Genomic structure of PHKA2 gene. Exons are indicated by boxes, introns by lines. Exons are to scale; introns are not. The
position of XLG I mutations is indicated above the gene, and the position of XLG II mutations is indicated below the gene. The start codon
in exon 1 and the stop codon in exon 33 are also indicated.
restriction digestion and/or electrophoresis. Specific con-
firmation methods and primer sequences are available
on request.
Results
Isolation of Genomic Clones
Seven cosmids and two P1 clones containing different
parts of the PHKA2 gene were isolated. Cosmids JH3
and JH4 were isolated by screening of a cosmid library
constructed from a 49, XXXXY lymphoblastoid cell line
(Blonden et al. 1989) with the PC1 clone as described
elsewhere (Hendrickx et al. 1993). JH3 has an insert of
˜44 kb, JH4 an insert of ˜36 kb. Both clones are located
in the 3′ end of the gene. Cosmid A159 was isolated
from an ICRF cosmid bank and was kindly provided by
Dr. Van de Vosse (Department of Genetics, University
of Leiden). A159 has an insert of ˜38 kb and is located
in the 5′ region of the gene. Additionally, an ICRF P1
library was screened with a small PCR product con-
taining the first 260 nucleotides of the PHKA2 cDNA,
yielding two positive P1 clones, O166 and P1426. Since
none of the isolated cosmid or P1 clones contained the
first exon of PHKA2, an ICRF X-specific cosmid bank
was screened once more with a PCR product containing
only exon 1. This yielded four additional cosmid
clones—F0552, I122, I102 and J0726—of which only
the first was used further.
Genomic Structure of the PHKA2 Gene
Two approaches were used to determine the genomic
structure of the PHKA2 gene. First, the genomic clones
JH3, JH4, A159, F0552, O166, and P1426 were frag-
mented either by sonication or by Sau3A restriction di-
gestion, and the fragments were ligated into either the
SmaI or the BamHI site of pUC18, respectively. Subse-
quently, the different subclones were screened with the
PHKA2 cDNA, and positive subclones were sequenced.
Alternatively, exon-exon PCR was performed with PCR
primers located in adjacent exons, followed by sequenc-
ing of the PCR fragments to determine the boundaries
of the intervening intron.
The genomic organization of the PHKA2 gene is
shown in figure 1. The gene contains 33 exons, spanning
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Table 3
PHKA2 Mutations in XLG I and XLG II
cDNA Change Protein Change
Exon (E)
or Intron (I) Type of Mutation Type of XLG Reference
70insT fs24 E1 Insertion, 1 bp I Burwinkel et al. (1998)
298delG fs100 E3 Deletion, 1 bp I Present study
394CrT H132Y E4 Missense II Burwinkel et al. (1996)
395ArC H132P E4 Missense II Burwinkel et al. (1996)
419del3 DF141 E4 Deletion, 3 bp I Van den Bergh et al. (1995)
556CrT R186C E6 Missense II Hendrickx et al. (1996); present study
557GrA R186H E6 Missense II Burwinkel et al. (1996);
Hendrickx et al. (1998); present study
567del22 fs189 E6 Deletion, 22 bp I Burwinkel et al. (1998)
567ArG K189E E6 Missense II Burwinkel et al. (1998)
565del6 DK189–T190 E6 Deletion, 6 bp II Present study
578GrT G193V E6 Missense II Hirono et al. (1995)
674del13 fs226 E7 Deletion, 13 bp I Present study
750del3 DT251 E8 Deletion, 3 bp II Hendrickx et al. (1996)
884GrA R295H E9 Missense I/II Present study
896ArG D299G E9 Missense II Burwinkel et al. (1996)
1054CrT R352X E11 Nonsense I Burwinkel et al. (1998)
1196CrT P399S E12 Missense I Burwinkel et al. (1998)
2296CrT Q766X E19 Nonsense I Hendrickx et al. (1995)
2452del24 DQ818–Y825 E22 Deletion, 24 bp I Burwinkel et al. (1998)
2858del 3 N953–L954I E26 Deletion, 3 bp I Burwinkel et al. (1998)
29081GrT DE26 I26 Splice site I Hendrickx et al. (1995)
3025CrT Q1009X E27 Nonsense I Hendrickx et al. (1995)
3146CrA S1049X E30 Nonsense I Hendrickx et al. (1995)
3331ins6 R1111insTR E31 Insertion, 6 bp II Hendrickx et al. (1996)
3341CrT T1114I E32 Missense II Hendrickx et al. (1996)
3355delAA fs1119 E32 Deletion, 2 bp I Present study
3373GrA E1125K E32 Missense I Present study
3505CrT Q1169X E32 Nonsense I Present study
3614CrT P1205L E33 Missense I Van den Bergh et al. (1995)
3619GrT G1207W E33 Missense I Burwinkel et al. (1998)
65 kb. Clone F0552 contains only exon 1, clone A159
exons 2–18, clone O166 exons 2–11, clone P1426 exons
2–28, clone JH4 exons 10–29, and clone JH3 exons
10–33. Exon 1 contains 171 bp from the 5′ UTR (Hirono
et al. 1995), the start codon, and the first 78 bp of the
open reading frame (ORF). Exon 33 contains base pairs
3538–3705 of the ORF and all 728 bp of the 3′ UTR.
The remaining 31 exons vary in size from 30 bp (exon
28) to 201 bp (exon 32) (table 2).
Except for introns 1 and 19, intron lengths have been
estimated by either exon-exon PCR, comparison of over-
lapping cosmid subclones, or sequencing (table 2). As
can be deduced from the estimated insert length (38 kb)
of clone A159 and the genomic length of exons 2–18,
intron 1 must be 5 kb. The length of intron 19 was
estimated to be ∼12 kb, as can be deduced from the
estimated length of clone JH4 (36 kb), which contains
exons 10–29. All intron-exon boundaries follow the gt
5′–donor and ag 3′–acceptor rule and are in good agree-
ment with the consensus for intron-donor and -acceptor
sequences in general (Shapiro and Senapathy 1987).
Exon and adjacent intron sequences have been submit-
ted to GenBank (accession numbers AF044540–
AF044572).
Mutation Analysis in the PHKA2 Gene
The availability of the genomic structure and the se-
quence of the intron-exon boundaries facilitated muta-
tion analysis using exon-by-exon scanning. On the basis
of the intron-exon boundaries, PCR primer pairs flank-
ing each exon were designed (table 2). By use of these
primers, the different PHKA2 exons of patients with
either XLG I or XLG II were amplified, and the PCR
products were analyzed, by SSCP analysis, for the pres-
ence of mutations. This yielded seven novel mutations
in eight unrelated families and two known mutations in
additional families (table 3).
Five novel XLG I mutations—including one nonsense,
three frameshift, and one missense mutation—were iden-
tified. The first mutation, identified in patient 1, is a
nonsense mutation changing the CAG codon (glutamine)
at amino acid position 1169 into a TAG stop codon
(Q1169X). Both the mother and sister of patient 1 are
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heterozygous carriers of the Q1169X mutation. Three
frameshift mutations have been identified. The first is
caused by deletion of guanine at nucleotide position 298
of the ORF, leading to both a frameshift at amino acid
position 100 (fs100) and a premature stop codon 48
codons downstream. This mutation was identified both
in patient 2, an isolated patient from the United King-
dom, and in his mother. The second frameshift, identified
in patient 3, an isolated Belgian patient, is caused by the
deletion of two adenine residues at nucleotide positions
3355 and 3356, which results in both a different reading
frame from amino acid 1119 (fs1119) and a premature
stop codon 83 codons downstream. A third frameshift
is caused by deletion of 13 nucleotides (positions
675–687). This leads to a frameshift starting from amino
acid 226 (fs226), resulting in an in-frame stop codon 44
codons downstream. This mutation was identified in pa-
tient 4, an isolated English patient, and in his mother.
The fifth XLG I mutation was identified in patient 5,
who belongs to one of the families used in the linkage
mapping of the XLG I gene (family 4 in Hendrickx et
al. 1993). This mutation was a missense mutation that
changes the GAA codon (glutamic acid) at amino acid
position 1125 into an AAA lysine codon (E1125K).
One novel XLG II mutation was identified. This mu-
tation, a deletion of two codons (six nucleotides) that
encode lysine and threonine at amino acids positions 189
and 190 (DK189–T190), was found in patient 6, an
isolated English patient, and in his mother. Additionally,
two previously described XLG II mutations, both of
which change the arginine codon at amino acid position
186, were shown to be present in additional patients
with XLG II. The R186H mutation (Burwinkel et al.
1996; Hendrickx et al. 1998) was found in patient 7,
who belongs to a family of French descent that contains
three patients in three generations. This patient was in-
cluded in an earlier study, by Maire et al. (1991). The
R186C mutation (Hendrickx et al. 1996) was found in
patient 8, who belongs to an American glycogenosis
family described by Keating et al. (1985).
Finally, a missense mutation that replaces the CGC
codon for arginine at amino acid position 295 with a
CAC histidine codon (R295H) was identified in both a
patient with XLG I and a patient with XLG II. The
patient with XLG I (patient 9) was an isolated American
patient with a pronounced PHK deficiency in both liver
and erythrocytes (both had 10% of the control mean)
and with an unusually severe phenotype (Tuchman et al.
1986). The patient with XLG II (patient 10) was an
isolated patient from the United Kingdom who had nor-
mal erythrocyte PHK activity (83% of the control mean).
All missense mutations were shown to be absent in a
panel of 50 healthy female controls, suggesting that they
are disease-causing mutations and not common poly-
morphisms. All mutations have been confirmed by either
PCR or modified PCR on genomic DNA of the patients,
followed by restriction digestion and/or electrophoresis
of the PCR product, excluding the possibility of PCR
artifacts.
Discussion
To facilitate mutation analysis in the PHKA2 gene of
patients with XLG, we determined its genomic structure.
The PHKA2 gene has an estimated length of 65 kb
and consists of 33 exons. Exon-by-exon mutation anal-
ysis of PHKA2 was performed by SSCP analysis, fol-
lowed by sequencing of aberrant PCR fragments. This
led to the identification of seven new mutations and two
previously described mutations in additional patients.
Together with the PHKA2 mutations reported in the
literature, 19 mutations have now been found in 18 pa-
tients with XLG I (2 different mutations, the substitution
of proline 399 by serine and of asparagine 953 and leu-
cine 954 by isoleucine, were present in one patient, but
it is not known which one causes XLG), and 12 mu-
tations have been found in 16 patients with XLG II (fig.
1 and table 3).
It is intriguing that mutations in the same gene,
PHKA2, lead to two different biochemical phenotypes:
(i) XLG I, with pronounced enzyme deficiency, and (ii)
XLG II, with normal PHK enzymatic activity in eryth-
rocytes and leukocytes and with variable activity in liver.
Previously, we have suggested a correlation between the
nature of the mutation and the biochemical phenotype:
XLG I mutations might be disruptive and lead to reduced
a subunit and PHK, whereas XLG II mutations might
lead to normal amounts of mutant a subunit causing
dysregulation of PHK in vivo (Hendrickx et al. 1996).
Since the in vitro assay of PHK measures only the activity
of the catalytic g subunit of PHK and not that of the
regulated holoenzyme, XLG II mutations might not
cause PHK deficiency in vitro. Twelve of the 19 XLG I
mutations identified so far are nonsense (R352X,
Q766X, Q1009X, S1049X, and Q1169X), splice site
(DE26), or frameshift (fs24, fs100, fs189, fs226, and
fs1119) mutations or large deletions (DQ818–Y825).
These mutations most likely result in a truncated or dis-
rupted a subunit, which is probably nonfunctional and
degrades quickly. In that case, the PHK deficiency in
patients with XLG I could be explained by the fact that
a PHK holoenzyme lacking the a subunit (bgd complex)
is unstable. I-strain mice that have an X-linked muscle
PHK deficiency due to a frameshift mutation in the mus-
cle a-subunit gene (Schneider et al. 1993) show absence
of the a but also of the b and g subunits, as well as a
reduction of the d subunit in muscle (Cohen et al. 1976;
Picton et al. 1983). Absence of the muscle a subunit
obviously leads to absence or reduction of the other PHK
subunits. Disruptive mutations in PHKA2 similarly may
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Table 4
PHK Enzyme Activities in XLG II
MUTATION
REFERENCE FOR
ACTIVITY IN PHK
(% OF CONTROL MEAN)
PATIENT Mutation Patient Erythrocytes Leukocytes Liver
H132Y Burwinkel et al. (1996) Hendrickx et al. (1994) 128 82 16
H132P Burwinkel et al. (1996) Lozano et al. (1994) 175 30
R186C Hendrickx et al. (1996) Hendrickx et al. (1994) 164
R186C 8 Present study Keating et al. (1985) 80
R186H Burwinkel et al. (1996) Bakker et al. (1991) 173 57 7
R186H Hendrickx et al. (1998) Gitzelmann (1957) 96 16
R186H 7 Present study Maire et al. (1991) 122
R186H Burwinkel et al. (1996) Maire et al. (1991) 156
K189E Burwinkel et al. (1998) Burwinkel et al. (1998) 400 10
DK189–T190 6 Present study Present study 177
G193V Hirono et al. (1995) Hirono et al. (1995) 200
DT251 Hendrickx et al. (1996) Hendrickx et al. (1996) 142
R295H 10 Present study Present study 83
D299G Burwinkel et al. (1996) Burwinkel et al. (1996) 160 30
R1111insTR Hendrickx et al. (1996) Hendrickx et al. (1994) 259 93
T1114I Hendrickx et al. (1996) Hendrickx et al. (1994) 548 77 132
cause reduced liver a subunit and, consequently, reduced
liver PHK.
In contrast to XLG I mutations, all XLG II mutations
identified so far are missense mutations (H132P, H132Y,
R186C, R186H, K189E, G193V, R295H, D299G, and
T1114I), small deletions (DK189–T190 and DT251) or
small insertions (R1111insTR), presumably imposing
only a minor influence on the primary protein structure
of the a subunit. As we have suggested previously (Hen-
drickx et al. 1996), several of these XLG II mutations
disrupt potential phosphorylation sites (the arginine
186–to–glycine 193 region, the threonine 251 residue,
and the arginine 1111–to–threonine 1114 region) that
may be involved in the regulation of PHK by phos-
phorylation of the a subunit. Therefore, mutations in
these regions might disturb the activation of PHK. Con-
sequently, XLG II patients would show a normal amount
of PHK, which, however, could not be activated by phos-
phorylation. The region containing arginine 186 to gly-
cine 193 seems to be especially important. Five different
XLG II mutations, identified in nine unrelated patients,
are clustered in these eight amino acids. Moreover, these
amino acids are completely conserved in all known a
subunits (Zander et al. 1988; Davidson et al. 1992;
Schneider et al. 1993; Wu¨llrich et al. 1993) and in the
Caenorhabditis elegans a-subunit homologue (Sulston
et al. 1992) and are very well conserved in the b subunit
(Kilimann et al. 1988; Wu¨llrich-Schmoll and Kilimann
1996).
For some of the XLG mutations, it is unclear whether
the proposed genotype-phenotype correlation holds.
First, seven XLG I mutations—including small deletions
involving amino acid F141 and amino acids N953 and
L954 and missense mutations that substitute R295,
P399, E1125, P1205, and G1207—do not result in a
truncated a subunit. Second, three XLG II mutation sites
(the histidine 132, arginine 295, and aspartic acid 299
residues) do not resemble any known functional protein
domains or motifs. Possibly, the residues mutated in
XLG I may be important for either the structure of the
a subunit or holoenzyme assembly, whereas the residues
mutated in XLG II may also have a regulatory function.
However, this will remain speculative until more infor-
mation is available about both the regulation of PHK
and the position of the respective residues in either the
folded a subunit or the assembled holoenzyme. Third,
the presence of the R295H mutation in both a patient
with XLG I and a patient with XLG II might be difficult
to reconcile with the proposed genotype-phenotype cor-
relation.
It is noteworthy that the PHK-enzyme assays in these
two patients have been performed in different labs. This
suggests that the specific conditions of the enzyme assay
may determine whether PHK is deficient in vitro—that
is, whether a patient is classified as having XLG I or
XLG II. This is corroborated by the fact that, when PHK
is determined by an alternative assay method that mea-
sures the activation of endogenous phosphorylase, pa-
tients with XLG II do show a PHK-enzyme deficiency
(Maire et al. 1991; Hendrickx et al. 1994). In this con-
text, it is also noteworthy that liver PHK shows a sig-
nificant variability in patients with XLG II (table 4).
Whereas liver PHK is deficient in most XLG II patients,
two patients showed normal activity. Most of these PHK
measurements have been performed in different labs,
probably under slightly different reaction conditions.
These minor differences in reaction conditions may be
responsible for the variability. Alternatively, since PHK
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is part of a cascade of enzymatic reactions, each of which
is influenced by a variety of factors, individual differ-
ences in one of these factors may also result in a varying
outcome of the enzyme assay, especially if the mutation
influences the regulation of the enzyme. As a conse-
quence, the classification of patients as having either
XLG I or XLG II, which is based on the in vitro PHK
activity, may not be correct in all cases. It would be
interesting to analyze the different enzyme-assay meth-
ods used by different laboratories, to find an explanation
for the variation in PHK activity in XLG II and to de-
velop an assay method that does detect a PHK deficiency
in XLG II. Additionally, the identification of more XLG
I mutations and XLG II mutations, which is facilitated
by the genomic structure of PHKA2, may significantly
extend our knowledge of the structural elements and
factors involved in the regulation of PHK. This and an
improved and standardized enzyme assay seem essential
to confirm and possibly to adjust the genotype-pheno-
type–correlation hypothesis.
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